Compare Stocks: SEPN, RYTM, TGTX, and ORKA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORKA Oruka Therapeutics	$107.96 +3.0%	$91.82	$14.34 ▼ $115.51	$7.15B	-0.34	787,185 shs	935,783 shs
RYTM Rhythm Pharmaceuticals	$110.00 +1.0%	$108.03	$74.50 ▼ $122.20	$7.54B	1.92	719,844 shs	523,136 shs
SEPN Septerna	$40.00 -1.9%	$36.85	$11.70 ▼ $51.10	$1.87B	2.29	432,036 shs	289,807 shs
TGTX TG Therapeutics	$54.27 +7.3%	$53.02	$26.76 ▼ $59.30	$8.31B	1.62	2.21 million shs	5.55 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORKA Oruka Therapeutics	0.00%	-2.77%	+17.41%	+78.12%	+649.72%
RYTM Rhythm Pharmaceuticals	0.00%	-4.75%	+7.15%	+25.23%	+11.45%
SEPN Septerna	0.00%	-10.11%	+19.51%	+41.04%	+260.69%
TGTX TG Therapeutics	0.00%	+11.35%	-2.22%	+39.62%	+91.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORKA Oruka Therapeutics	$107.96 +3.0%	$91.82	$14.34 ▼ $115.51	$7.15B	-0.34	787,185 shs	935,783 shs
RYTM Rhythm Pharmaceuticals	$110.00 +1.0%	$108.03	$74.50 ▼ $122.20	$7.54B	1.92	719,844 shs	523,136 shs
SEPN Septerna	$40.00 -1.9%	$36.85	$11.70 ▼ $51.10	$1.87B	2.29	432,036 shs	289,807 shs
TGTX TG Therapeutics	$54.27 +7.3%	$53.02	$26.76 ▼ $59.30	$8.31B	1.62	2.21 million shs	5.55 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORKA Oruka Therapeutics	0.00%	-2.77%	+17.41%	+78.12%	+649.72%
RYTM Rhythm Pharmaceuticals	0.00%	-4.75%	+7.15%	+25.23%	+11.45%
SEPN Septerna	0.00%	-10.11%	+19.51%	+41.04%	+260.69%
TGTX TG Therapeutics	0.00%	+11.35%	-2.22%	+39.62%	+91.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ORKA Oruka Therapeutics	2.82	Moderate Buy	$134.30	24.40% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$142.44	29.49% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	31.11% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	16.09% Upside

Current Analyst Ratings Breakdown

Latest SEPN, RYTM, TGTX, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	SEPN Septerna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$38.00 ➝ $48.00
8/13/2026	SEPN Septerna	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$43.00 ➝ $62.00
8/12/2026	SEPN Septerna	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $50.00
8/12/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
8/11/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$49.00
8/11/2026	SEPN Septerna	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
8/11/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $51.00
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$16.79 per share	N/A
RYTM Rhythm Pharmaceuticals	$189.76M	39.73	N/A	N/A	$1.50 per share	73.33
SEPN Septerna	$45.95M	40.64	N/A	N/A	$8.29 per share	4.83
TGTX TG Therapeutics	$616.29M	13.48	$2.80 per share	19.37	$3.95 per share	13.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.81	20.48	2.33	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest SEPN, RYTM, TGTX, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ORKA Oruka Therapeutics	N/A	38.51	38.51
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SEPN Septerna	N/A	4.99	4.99
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ORKA Oruka Therapeutics	56.44%
RYTM Rhythm Pharmaceuticals	N/A
SEPN Septerna	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ORKA Oruka Therapeutics	23.49%
RYTM Rhythm Pharmaceuticals	5.90%
SEPN Septerna	5.80%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ORKA Oruka Therapeutics	N/A	66.21 million	50.66 million	N/A
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
SEPN Septerna	N/A	46.68 million	43.97 million	N/A
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

SEPN, RYTM, TGTX, and ORKA Headlines

Recent News About These Companies

Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX

August 23 at 5:19 AM | marketbeat.com

235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG

August 23 at 3:36 AM | marketbeat.com

Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

August 23 at 1:20 AM | americanbankingnews.com

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

August 22 at 10:00 AM | seekingalpha.com

BlackRock Inc. Takes Position in TG Therapeutics, Inc. $TGTX

August 22 at 3:21 AM | marketbeat.com

TGTX stock alert: What to know as takeover rumors swirl around TG Therapeutics

August 21 at 11:49 PM | msn.com

TG Therapeutics (NASDAQ:TGTX) Trading 10.1% Higher - Should You Buy?

August 21 at 12:19 PM | marketbeat.com

TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

August 21 at 10:59 AM | marketbeat.com

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

August 17, 2026 | marketbeat.com

Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Hold" from Analysts

August 13, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP

August 10, 2026 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages

August 8, 2026 | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

August 7, 2026 | marketbeat.com

California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX

August 6, 2026 | marketbeat.com

HC Wainwright Expects Higher Earnings for TG Therapeutics

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co.

August 5, 2026 | marketbeat.com

Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Stock Holdings Boosted by Dimensional Fund Advisors LP

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN, RYTM, TGTX, and ORKA Company Descriptions

Oruka Therapeutics NASDAQ:ORKA

$107.96 +3.10 (+2.96%)

As of 08/21/2026 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rhythm Pharmaceuticals NASDAQ:RYTM

$110.00 +1.08 (+0.99%)

As of 08/21/2026 04:00 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Septerna NASDAQ:SEPN

$40.00 -0.79 (-1.94%)

As of 08/21/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

TG Therapeutics NASDAQ:TGTX

$54.27 +3.71 (+7.34%)

As of 08/21/2026 04:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEPN, RYTM, TGTX, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEPN, RYTM, TGTX, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEPN, RYTM, TGTX, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN, RYTM, TGTX, and ORKA Company Descriptions

Oruka Therapeutics NASDAQ:ORKA

Rhythm Pharmaceuticals NASDAQ:RYTM

Septerna NASDAQ:SEPN

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEPN, RYTM, TGTX, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEPN, RYTM, TGTX, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEPN, RYTM, TGTX, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN, RYTM, TGTX, and ORKA Company Descriptions

Oruka Therapeutics NASDAQ:ORKA

Rhythm Pharmaceuticals NASDAQ:RYTM

Septerna NASDAQ:SEPN

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools